Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1390532
European Journal of Endocrinology, Vol 139, Issue 5, 532-536
Copyright © 1998 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drake, W.
Right arrow Articles by Monson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drake, W.
Right arrow Articles by Monson, J.
Case Reports

Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia

WM Drake, F Miraki, A Siddiqi, M Yateman, NC Barnes, C Camacho-Hubner, and JP Monson

Department of Endocrinology, St Bartholomew's Hospital, London, UK.

Mesenchymal tumours are a well recognised cause of spontaneous hypoglycaemia. The mechanism is thought to relate to hypersecretion by tumour cells of high molecular mass insulin-like growth factor-II (pro-IGF-II), with consequent suppression of growth hormone (GH) secretion. The use of recombinant human (rh)GH has been reported to alleviate hypoglycaemia in non-islet cell tumour hypoglycaemia, and the mechanism is thought to relate to GH-mediated increments in serum levels of IGF-binding protein-3 (IGFBP-3), thereby reducing the bioavailability of IGF-II. We report the effect of increasing doses of rhGH on the clinical condition and serum IGF-I and IGFBP-3 levels in two patients with solitary pleural fibrous tumours causing severe hypoglycaemia. Hypoglycaemia was successfully alleviated in each patient although, despite using large doses of rhGH, the observed increments in IGFBP-3 were only modest. We postulate that the beneficial effects of rhGH in this situation are likely to be multifactorial and not simply related to increments in serum IGFBP-3 levels.


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Kaltsas, G. M. Besser, and A. B. Grossman
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Endocr. Rev., June 1, 2004; 25(3): 458 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
S Ford-Dunn, A Smith, and N Sykes
Tumour-induced hypoglycaemia
Palliative Medicine, June 1, 2002; 16(4): 357 - 358.
[PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Kaltsas, M. Korbonits, E. Heintz, J. J. Mukherjee, P. J. Jenkins, S. L. Chew, R. Reznek, J. P. Monson, G. M. Besser, R. Foley, et al.
Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 895 - 902.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 European Society of Endocrinology.